

The Biometric Society report notes that "On the question of cardiovascular mortality due to tolbutamide and phenformin we consider that the UGDP trial has raised suspicions which cannot be dismissed on the basis of other evidence presently available." However, we believe the Biometric report incorrectly minimizes some of the evidence which it analyzes, as in the case of the Paasikivi study which is inconsistent with their thesis of the toxicity of tolbutamide. They omit a recent report of a prospective study which has become a landmark in the field of epidemiology, that of the Framingham group. We have included a copy of this report, published in the American Journal of Cardiology, as an appendix to our testimony.

The Biometric group then focuses upon a critical issue:

"There remains the question of generalization of these findings. As has been frequently pointed out, the conditions of drug use in this study were, to some extent, abnormal. Tolbutamide dosage is varied in practice and the patient unable to obtain inadequate control on tolbutamide could be shifted to insulin."